REQUEST PRICE

Fields with * are required
Premium Phosphosite-Specific 7TM Antibodies
Novel Tools for Your GPCR Research
Select Your Country of Delivery below

GPR35 Receptor Antibodies

Close filters
No results were found for the filter!
NEW
pS298/pS301-mGPR35 (phospho-mouse GPR35 Antibody)
pS298/pS301-mGPR35 (phospho-mouse GPR35 Antibody)
Serine298/Serine301 (S298/S301) is a major phosphorylation site of the mouse GPR35 receptor. The pS298/pS301-mGPR35 antibody detects phosphorylation in response to high-efficacy agonists. S298/S301 phosphorylation is a key regulator of...
$ 350.00
NEW
pS298/pS301-mGPR35 (1 mg phospho-mouse GPR35 Phospho-Peptide)
pS298/pS301-mGPR35 (1 mg phospho-mouse GPR35...
Serine298/Serine301 (S298/S301) is a major phosphorylation site of the mouse GPR35 receptor. The pS298/pS301-mGPR35 antibody detects phosphorylation in response to high-efficacy agonists. S298/S301 phosphorylation is a key regulator of...
$ 350.00
NEW
pS298/pS301-mGPR35 (1 mg phospho-mouse GPR35 NON-Phospho-Peptide)
pS298/pS301-mGPR35 (1 mg phospho-mouse GPR35...
Serine298/Serine301 (S298/S301) is a major phosphorylation site of the mouse GPR35 receptor. The pS298/pS301-mGPR35 antibody detects phosphorylation in response to high-efficacy agonists. S298/S301 phosphorylation is a key regulator of...
$ 350.00
NEW
pS300/pS303-hGPR35 (1 mg phospho-human GPR35 NON-Phospho-Peptide)
pS300/pS303-hGPR35 (1 mg phospho-human GPR35...
Serine300/Serine303 (S300/S303) is a major phosphorylation site of the human GPR35 receptor. The pS300/pS303-hGPR35 antibody detects phosphorylation in response to high-efficacy agonists. S300/S303 phosphorylation is a key regulator of...
$ 350.00
NEW
pS300/pS303-hGPR35 (1 mg phospho-human GPR35 Phospho-Peptide)
pS300/pS303-hGPR35 (1 mg phospho-human GPR35...
Serine300/Serine303 (S300/S303) is a major phosphorylation site of the human GPR35 receptor. The pS300/pS303-hGPR35 antibody detects phosphorylation in response to high-efficacy agonists. S300/S303 phosphorylation is a key regulator of...
$ 350.00
NEW
pS300/pS303-hGPR35 (phospho-human GPR35 Antibody)
pS300/pS303-hGPR35 (phospho-human GPR35 Antibody)
Serine300/Serine303 (S300/S303) is a major phosphorylation site of the human GPR35 receptor. The pS300/pS303-hGPR35 antibody detects phosphorylation in response to high-efficacy agonists. S300/S303 phosphorylation is a key regulator of...
$ 350.00

GPR35

Although GPR35 is still considered an orphan receptor, there have been attempts to deorphanize it by identifying endogenous molecules that can activate the receptor. All of the currently proposed ligands are either unselective towards GPR35, or they lack high potency, a characteristic feature of natural ligands.Kynurenic acid was first reported as an agonist of GPR35, but controversy remains whether the endogenous ligand reaches sufficient tissue concentrations to activate the receptor. 2-Acyl lysophosphatidic acid (2-oleoyl-LPA) has also been proposed as an endogenous ligand but these results were not replicated in a recent β-arrestin assay. Zaprinast, a cyclic GMP-selective phosphodiesterase (PDE5A/PDE6) inhibitor, has become widely used as a surrogate agonist to investigate GPR35 pharmacology and signalling. GPR35 is also activated by the loop diuretic drugs bumetanide and furosemide and the pharmaceutical adjunct pamoic acid. GPR35 is expressed by dendritic cells, macrophages, and granulocytes, all of which show chemotactic response to CXCL17. It is unclear whether the migration stimulatory response to CXCL17 is mediated by direct interaction with GPR35. GPR35 desensitization, β-arrestin recruitment and internalization are regulated by phosphorylation of carboxyl-terminal serine300/serine303 (pS300/pS303-GPR35). This nomenclature refers to the human GPR35 receptor. The mouse GPR35 receptor is related by phosphorylation of carboxyl-terminal serine298/serine301 (pS298/pS301-mGPR35) and serine305 (pS305-mGPR35). For more information on GPR35 pharmacology please refer to the IUPHAR database. For further reading refer to:

Davenport AP, Alexander SP, Sharman JL, Pawson AJ, Benson HE, Monaghan AE, Liew WC, Mpamhanga CP, Bonner TI, Neubig RR, Pin JP, Spedding M, Harmar AJ. International Union of Basic and Clinical Pharmacology. LXXXVIII. G protein-coupled receptor list: recommendations for new pairings with cognate ligands. Pharmacol Rev. 2013 May 17;65(3):967-86. doi: 10.1124/pr.112.007179. PMID: 23686350; PMCID: PMC3698937.

Although GPR35 is still considered an orphan receptor, there have been attempts to deorphanize it by identifying endogenous molecules that can activate the receptor. All of the currently... read more »
Close window
GPR35 Receptor Antibodies

GPR35

Although GPR35 is still considered an orphan receptor, there have been attempts to deorphanize it by identifying endogenous molecules that can activate the receptor. All of the currently proposed ligands are either unselective towards GPR35, or they lack high potency, a characteristic feature of natural ligands.Kynurenic acid was first reported as an agonist of GPR35, but controversy remains whether the endogenous ligand reaches sufficient tissue concentrations to activate the receptor. 2-Acyl lysophosphatidic acid (2-oleoyl-LPA) has also been proposed as an endogenous ligand but these results were not replicated in a recent β-arrestin assay. Zaprinast, a cyclic GMP-selective phosphodiesterase (PDE5A/PDE6) inhibitor, has become widely used as a surrogate agonist to investigate GPR35 pharmacology and signalling. GPR35 is also activated by the loop diuretic drugs bumetanide and furosemide and the pharmaceutical adjunct pamoic acid. GPR35 is expressed by dendritic cells, macrophages, and granulocytes, all of which show chemotactic response to CXCL17. It is unclear whether the migration stimulatory response to CXCL17 is mediated by direct interaction with GPR35. GPR35 desensitization, β-arrestin recruitment and internalization are regulated by phosphorylation of carboxyl-terminal serine300/serine303 (pS300/pS303-GPR35). This nomenclature refers to the human GPR35 receptor. The mouse GPR35 receptor is related by phosphorylation of carboxyl-terminal serine298/serine301 (pS298/pS301-mGPR35) and serine305 (pS305-mGPR35). For more information on GPR35 pharmacology please refer to the IUPHAR database. For further reading refer to:

Davenport AP, Alexander SP, Sharman JL, Pawson AJ, Benson HE, Monaghan AE, Liew WC, Mpamhanga CP, Bonner TI, Neubig RR, Pin JP, Spedding M, Harmar AJ. International Union of Basic and Clinical Pharmacology. LXXXVIII. G protein-coupled receptor list: recommendations for new pairings with cognate ligands. Pharmacol Rev. 2013 May 17;65(3):967-86. doi: 10.1124/pr.112.007179. PMID: 23686350; PMCID: PMC3698937.

Recently viewed